Objective:To analyse the key compounds,targets and pathways of the treatment of non‑alcoholic fatty liver disease(NAFLD)by Jianwei Gexia Zhuyu Decoction based on network pharmacology,in order to explore the molecular ...Objective:To analyse the key compounds,targets and pathways of the treatment of non‑alcoholic fatty liver disease(NAFLD)by Jianwei Gexia Zhuyu Decoction based on network pharmacology,in order to explore the molecular mechanism of its therapeutic effects.Methods:The differential genes between sick and normal conditions were screened by GEO‑Datasets,and the heat map and volcano map were drawn.The active compounds in Jianwei Gexia Zhuyu Decoction were searched by TCMSP platform and Drugbank database.OB≥30%and DL≥0.18 were set as thresholds to screen potential active compounds and action targets.The molecular target maps of Jianwei Gexia Zhuyu Decoction and NAFLD differential genes were constructed,and the PPI network and network topology parameters were obtained by STRING database.The PPI network and network topology parameters were visually analyzed by Cytoscape,and the core regulatory genes were screened.At the same time,the SwissDock platform was used to dock the main active components with the target.The main pathways were determined by GO biological function enrichment analysis and KEGG metabolic pathway enrichment analysis by DAVID.Results:After screening,377 differential genes(127 up‑regulated genes and 250 down‑regulated genes),225 active compounds of Jianwei Gexia Zhuyu Decoction,308 corresponding targets were obtained;14 key targets were screened,corresponding to 168 compounds,and the key targets involved MYC,FOSL2,FOS,etc.The results of GO functional enrichment analysis showed that Jianwei Gexia Zhuyu Decoction mainly regulated the activity expression of DNA binding transcriptional activator and the specific transcription of RNA polymeraseⅡ;The results of molecular docking showed that the main active components quercetin and baicalein had good binding activity with VCAM1,HSPB1,MYC,JUN and so on;The results of KEGG enrichment analysis showed that it was mainly involved in IL‑17 signal pathway,Wnt receptor signal pathway,NF‑κB signal pathway,TNF signal pathway and AGE‑RAGE signal pathway in diabetic complications.Conclusion:Through the interaction of multi‑components and multi‑targets,Jianwei Gexia Zhuyu Decoction has achieved the goal of overall treatment of NAFLD from many ways.The application of network pharmacology provides a new research approach and scientific basis for further study on the mechanism of Jianwei Gexia Zhuyu Decoction in the treatment of NAFLD.展开更多
目的探索舒肝健胃丸联合埃索美拉唑镁肠溶片、莫沙必利片治疗胃食管反流病患者的效果。方法87例胃食管反流病患者,随机分为对照组(43例)及实验组(44例)。对照组患者服用埃索美拉唑镁肠溶片联合莫沙必利片治疗,实验组患者在对照组基础上...目的探索舒肝健胃丸联合埃索美拉唑镁肠溶片、莫沙必利片治疗胃食管反流病患者的效果。方法87例胃食管反流病患者,随机分为对照组(43例)及实验组(44例)。对照组患者服用埃索美拉唑镁肠溶片联合莫沙必利片治疗,实验组患者在对照组基础上结合舒肝健胃丸治疗。比较两组患者治疗前后的反流性疾病问卷(RDQ)评分及食管24 h pH检测指标(反流持续≥5 min次数、最长反流持续时间、pH<4的总时间百分比、DeMeester评分)。结果治疗后,实验组患者的反酸、反流、烧心、非心源性胸痛评分及RDQ总分分别为(3.83±1.49)、(3.17±1.28)、(2.97±1.14)、(2.69±1.24)、(12.21±3.59)分,均低于对照组的(4.55±1.24)、(4.06±1.62)、(3.61±1.38)、(3.03±1.35)、(14.89±4.19)分,差异具有统计学意义(P<0.05)。治疗后,实验组患者的反流持续≥5 min次数(2.96±2.34)次少于对照组的(3.85±1.23)次,最长反流持续时间(7.93±2.44)min短于对照组的(11.43±3.20)min,pH<4的总时间百分比(6.02±3.25)%及DeMeester评分(8.07±3.06)分低于对照组的(7.55±3.40)%、(10.48±2.68)分,差异具有统计学意义(P<0.05)。结论采用舒肝健胃丸联合埃索美拉唑镁肠溶片、莫沙必利片治疗胃食管反流病的效果确切。展开更多
基金National Natural Science Foundation of China(NO.81603418)。
文摘Objective:To analyse the key compounds,targets and pathways of the treatment of non‑alcoholic fatty liver disease(NAFLD)by Jianwei Gexia Zhuyu Decoction based on network pharmacology,in order to explore the molecular mechanism of its therapeutic effects.Methods:The differential genes between sick and normal conditions were screened by GEO‑Datasets,and the heat map and volcano map were drawn.The active compounds in Jianwei Gexia Zhuyu Decoction were searched by TCMSP platform and Drugbank database.OB≥30%and DL≥0.18 were set as thresholds to screen potential active compounds and action targets.The molecular target maps of Jianwei Gexia Zhuyu Decoction and NAFLD differential genes were constructed,and the PPI network and network topology parameters were obtained by STRING database.The PPI network and network topology parameters were visually analyzed by Cytoscape,and the core regulatory genes were screened.At the same time,the SwissDock platform was used to dock the main active components with the target.The main pathways were determined by GO biological function enrichment analysis and KEGG metabolic pathway enrichment analysis by DAVID.Results:After screening,377 differential genes(127 up‑regulated genes and 250 down‑regulated genes),225 active compounds of Jianwei Gexia Zhuyu Decoction,308 corresponding targets were obtained;14 key targets were screened,corresponding to 168 compounds,and the key targets involved MYC,FOSL2,FOS,etc.The results of GO functional enrichment analysis showed that Jianwei Gexia Zhuyu Decoction mainly regulated the activity expression of DNA binding transcriptional activator and the specific transcription of RNA polymeraseⅡ;The results of molecular docking showed that the main active components quercetin and baicalein had good binding activity with VCAM1,HSPB1,MYC,JUN and so on;The results of KEGG enrichment analysis showed that it was mainly involved in IL‑17 signal pathway,Wnt receptor signal pathway,NF‑κB signal pathway,TNF signal pathway and AGE‑RAGE signal pathway in diabetic complications.Conclusion:Through the interaction of multi‑components and multi‑targets,Jianwei Gexia Zhuyu Decoction has achieved the goal of overall treatment of NAFLD from many ways.The application of network pharmacology provides a new research approach and scientific basis for further study on the mechanism of Jianwei Gexia Zhuyu Decoction in the treatment of NAFLD.
文摘目的探索舒肝健胃丸联合埃索美拉唑镁肠溶片、莫沙必利片治疗胃食管反流病患者的效果。方法87例胃食管反流病患者,随机分为对照组(43例)及实验组(44例)。对照组患者服用埃索美拉唑镁肠溶片联合莫沙必利片治疗,实验组患者在对照组基础上结合舒肝健胃丸治疗。比较两组患者治疗前后的反流性疾病问卷(RDQ)评分及食管24 h pH检测指标(反流持续≥5 min次数、最长反流持续时间、pH<4的总时间百分比、DeMeester评分)。结果治疗后,实验组患者的反酸、反流、烧心、非心源性胸痛评分及RDQ总分分别为(3.83±1.49)、(3.17±1.28)、(2.97±1.14)、(2.69±1.24)、(12.21±3.59)分,均低于对照组的(4.55±1.24)、(4.06±1.62)、(3.61±1.38)、(3.03±1.35)、(14.89±4.19)分,差异具有统计学意义(P<0.05)。治疗后,实验组患者的反流持续≥5 min次数(2.96±2.34)次少于对照组的(3.85±1.23)次,最长反流持续时间(7.93±2.44)min短于对照组的(11.43±3.20)min,pH<4的总时间百分比(6.02±3.25)%及DeMeester评分(8.07±3.06)分低于对照组的(7.55±3.40)%、(10.48±2.68)分,差异具有统计学意义(P<0.05)。结论采用舒肝健胃丸联合埃索美拉唑镁肠溶片、莫沙必利片治疗胃食管反流病的效果确切。